Researches announce successful intra-neuronal antibody delivery without a viral vector
CytoDel, Inc., a privately-held corporation, today announces the publication of preclinical data on the company’s lead product, Cyto-111, in the
Read more
CytoDel, Inc., a privately-held corporation, today announces the publication of preclinical data on the company’s lead product, Cyto-111, in the
Read more